News

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

Catch up on coverage from the third day of South Beach Symposium 2026.

GLP-1 therapies represent a paradigm shift requiring dermatology to integrate metabolic, medical, and aesthetic care.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

Glynis Ablon, MD, FAAD, examines the intersection of menopause, hormones, and dermatologic health.

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

At South Beach Symposium 2026, Benjamin Ungar, MD, discussed safer, long-term approaches for seborrheic dermatitis.

Catch up on coverage from the second day of South Beach Symposium 2026.

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Catch up on coverage from the first day of South Beach Symposium 2026.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

At MOPD 2026, Kristina Derrick, MD, ScM, links teen acne to hormones and metabolism, highlighting PCOS clues and antiandrogen therapies.

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

As SBS kicks off in South Beach Miami, scroll through faces familiar to Dermatology Times presenting at the symposium.

Aminex Therapeutics has initiated a trial evaluating AMXT 1501 and DFMO, with implications for dermatologists managing advanced melanoma.

Sagimet and Ascletis shared denifanstat's 52-week safety results plus sustained improvements, highlighting a once-daily oral FASN inhibitor for acne.

Discover how Nutrafol Men 50+ addresses age-related hair loss in men, combining targeted ingredients for optimal scalp health and hair quality.

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Catch up on the latest research posters presented at last month's conferences, compiled all in one place for dermatology professionals.

La Roche-Posay and the Oncology Nursing Society mark World Cancer Day with a first-of-its-kind tool, improving cancer care in patients with skin of color.